Literature DB >> 6154549

Radioimmunoassay for human pancreatic secretory trypsin inhibitor: measurement of serum pancreatic secretory trypsin inhibitor in normal subjects and subjects with pancreatic diseases.

T Kitahara, Y Takatsuka, K I Fujimoto, S Tanaka, M Ogawa, G Kosaki.   

Abstract

A reliable radioimmunoassay (RIA) for human pancreatic secretory trypsin inhibitor (PSTI) has been developed. The method is highly sensitive (0.4 ng/ml), reproducible and specific. A good parallel relationship was observed between the standard curve and dilution curves for serum and urine. The PSTI bound to trypsin-alpha 2-macroglobulin complexes was found not to be immunoreactive, whereas a part of the psti-trypsin complex was immuno-reactive. In healthy individuals, serum PSTI level ranged from 5.4 ng/ml to 16.0 ng/ml, the average being 11.3 ng/ml (S.D. +/- 2.7). Elevated values were observed in patients with acute pancreatitis (highest value 3200 ng/ml), and in some patients with chronic relapsing pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154549     DOI: 10.1016/0009-8981(80)90205-3

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  14 in total

Review 1.  Granzyme A activates another way to die.

Authors:  Judy Lieberman
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Immunoreactive pancreatic secretory trypsin inhibitor in normal, inflammatory and neoplastic gallbladders.

Authors:  H Bohe; M Bohe; C Lindström; K Ohlsson
Journal:  Gastroenterol Jpn       Date:  1991-02

3.  Production and secretion of pancreatic secretory trypsin inhibitor in normal human small intestine.

Authors:  H Bohe; M Bohe; E Lundberg; A Polling; K Ohlsson
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

Review 4.  Death by a thousand cuts: granzyme pathways of programmed cell death.

Authors:  Dipanjan Chowdhury; Judy Lieberman
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

5.  Protease inhibitor and defective proteolysis in cystic fibrosis.

Authors:  M C Hsieh; H K Berry
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

6.  Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.

Authors:  M Plebani; D Basso; C Fabris; T Meggiato; G Del Favero; M P Panozzo; P Fogar; D Faggian; C Angonese; A Burlina
Journal:  Klin Wochenschr       Date:  1989-10-17

7.  Appearance mechanism and molecular heterogeneity of serum pancreatic secretory trypsin inhibitor (PSTI).

Authors:  I Nakano; A Funakoshi; T Sumii; K Miyazaki; Y Oogami; T Kimura; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1985-08

8.  The measurement of serum immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal cancer and pancreatic disease.

Authors:  K Satake; A Inui; T Sogabe; Y Yoshii; B Nakata; H Tanaka; Y S Chung; A Hiura; K Umeyama
Journal:  Int J Pancreatol       Date:  1988-07

9.  Pancreatic tissue damage by transcatheter arterial embolization for hepatoma.

Authors:  K N Khan; K Nakata; M Shima; Y Kusumoto; N Ishii; T Koji; S Nagataki
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

10.  Carboxyl ester lipase in human tissues and in acute pancreatitis.

Authors:  H J Aho; B Sternby; M Kallajoki; T J Nevalainen
Journal:  Int J Pancreatol       Date:  1989-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.